Clevidipine nanoparticles and pharmaceutical compositions thereof
AssigneeChiesi Farmaceutici S.p.A.
InventorsRajeshwar MOTHERAM, David HANLEY, Akif Emre TURELI, Monika KANTER
Life of this patent
Estimating the term…
Abstract
Provided is a pharmaceutical composition comprising clevidipine in a sterile, ready to use, physically stable, aqueous dispersion of nanoparticles that stabilizes clevidipine against formation of impurities and is suitable for parenteral administration.
Claims37
(canceled)
(canceled)
(canceled)
The therapeutic nanoparticle according to claim 25 further comprising at least one excipient that is water soluble or water insoluble or combinations thereof.
A method of treating hypertension, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition to a patient in need thereof wherein the pharmaceutical composition comprises a therapeutic nanoparticle, and a water soluble excipient, wherein said water soluble excipient is vitamin E TPGS, polysorbate 80, polysorbate 20, Triton X-100, lauryl glucoside, NP-40, oleyl alcohol, sorbitans, stearyl alcohol, nonoxynols, Cremophore, Solutol HS 15, plutonic acid, sodium dodecyl sulfate, bile acid salts, polyethylene glycol or polypropylene glycol, or combinations thereof.
A method of treating hypertension, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition to a patient in need thereof wherein the pharmaceutical composition comprises a therapeutic nanoparticle, and a water insoluble excipient, wherein said water insoluble excipient is vitamin E, and its derivatives, bile acid and its derivatives and phospholipid derivatives, lecithin, lysolecithin, phosphotidylserine, glycerophosphocholine, oleic acid, glycerol, inositol, diethylenetriaminepentaaceticacid, polyoxyethylene castor, polyoxyethylenehydrogenated castor oil base or polyoxyethylene sorbitan monolaurate, or combinations thereof, and wherein the therapeutic nanoparticle comprises clevidipine or a pharmaceutically acceptable salt thereof.
The therapeutic nanoparticle according to claim 25, comprising at least one water soluble excipient and at least one water insoluble excipient.
The therapeutic nanoparticle according to claim 25, wherein said nanoparticle is less than 900 nm in size.
The therapeutic nanoparticle according to claim 25, wherein said nanoparticle is less than 800 nm in size.
The therapeutic nanoparticle according to claim 25, wherein said nanoparticle is less than 700 nm in size.
The therapeutic nanoparticle according to claim 25, wherein said nanoparticle is less than 600 nm in size.
The therapeutic nanoparticle according to claim 25, wherein said nanoparticle is less than 500 nm in size.
The therapeutic nanoparticle according to claim 25, wherein said nanoparticle is less than 400 nm in size.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of treating hypertension, comprising the step of administering a therapeutically effective amount of a pharmaceutical composition to a patient in need thereof wherein the pharmaceutical composition comprises a therapeutic nanoparticle, wherein the therapeutic nanoparticle comprises clevidipine or a pharmaceutically acceptable salt thereof, and at least one excipient.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.